With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33100-27-5,1,4,7,10,13-Pentaoxacyclopentadecane,as a common compound, the synthetic route is as follows.
EXAMPLE 1 A mixture of 1-[3-(naphth-2-ylmethoxy)phenyl]cyclohexanol (0.65 g), sodium hydride (0.096 g of a 50percent w/w dispersion in mineral oil), 1,4,7,10,13-pentaoxacyclopentadecane (hereinafter 15-crown-5, (0.06 g) and tetrahydrofuran (10 ml) was stirred at ambient temperature for 15 minutes. methyl iodide (0.12 ml) was added and the mixture was stirred at ambient temperature for 15 hours. The mixture was evaporated and the residue was partitioned between diethyl ether and water. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried (MgSO4 and evaporated. The residue was purified by column chromatography using a 9:1 v/v mixture of methylene chloride and diethyl ether as eluent. There was thus obtained 1-methoxy-1-[3-(naphth-2-ylmethoxy)phenyl]cyclohexane (0.35 g, 54percent), m.p. 74-75¡ãC. The 1-[3-(naphth-2-ylmethoxy)phenyl]cyclohexanol starting material was obtained as follows:-.
The synthetic route of 33100-27-5 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; IMPERIAL CHEMICAL INDUSTRIES PLC; ICI-PHARMA; EP375452; (1994); B1;,
Chiral Catalysts
Chiral catalysts – SlideShare